Highlights

Getting patients into remission is not the major problem, the major problem is preventing relapse, and so achieving MRD negativity. I think an unmet need would be targeting MRD with relatively non-toxic agents.

I think magrolimab is a very interesting drug, particularly in combination with azacitidine. The population being targeted is particularly poor-risk patients with adverse cytogenetics and TP53 mutations. This is a group of patients that do badly with intensive therapy, that don’t do as well with non-intensive therapies like venetoclax and azacitidine. They respond, but the duration of response is short. So, I think the combination triple therapy with ven/aza and magrolimab, the preliminary data that I have seen looks definitely an improvement over other approaches. So, I think it’s a very interesting drug, [for a] population of patients for whom the current treatment options are extremely poor.